Document is current
Any future updates will be listed below
-
Authors
Peng, Dandan
Qin, Furong
Fu, Minyang
Jiang, Ning
Wang, Manni
Wang, Zhenling
Wei, Xiawei https://orcid.org/0000-0002-6513-6422
-
Funding
Funding for this research was provided by:
the Sichuan Province Distinguished Young Science and Technology Program (2019JD100008)
- License Information
-
More Information
Article History
Received: 20 January 2026
Revised: 5 February 2026
Accepted: 12 February 2026
First Online: 2 March 2026
Declarations
:
: The study was conducted at Chengdu Huaxi Haichi Pharmaceutical Technology Co., Ltd. (Chengdu, China) in strict accordance with the approved study protocol, institutional standard operating procedures, and relevant animal welfare regulations. All procedures complied with the Principles of Good Laboratory Practice (GLP) as defined by the CFDA (2003), FDA (21 CFR Part 58), and OECD (ENV/MC/CHEM(98)17). The facility is GLP-certified by both the National Medical Products Administration (NMPA, formerly CFDA) and OECD, and is fully accredited by the AAALAC International. All animal experimental protocols were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of the facility (Approval No.: IACUC-A2017007).
: Not applicable.
: Jumbo Drug Bank Co. Ltd. provided the financial support to this preclinical trial. Ning Jiang and Xiawei Wei are employees of this Company and declare a potential conflict of interest. The other authors have no conflicts of interest to declare.
